CRI market research report

PD-1/PDL-1 Inhibitor Market – A Global and Regional Analysis: Focus on Epidemiology, Product, and Region – Analysis and Forecast, 2022-2032

$5250 – $8100

There are seven product currently available in the market. The first entrant Keytruda drwas a significant share of the market followed by second entrant Opdivo. Imfinzi and Tecentriq also have their combined market share below 20%.

SKU: BHL1259SA Category: Tag:

Description

Global PD-1/PDL-1 Inhibitor Market Overview

Programmed cell death 1 (PD-1) inhibitor and programmed death ligand 1 (PD-L1) inhibitor are therapeutic agents that inhibit binding together of these checkpoint proteins on immune cells, eventually preventing tumors to escape the host immune defense mechanism and control the disease progression. The first PD-1 inhibitor Opdivo developed by Merck Sharp and Dhome (MSD) entered the market in 2014. Jemperli from GSK is the latest market entrant in the segment.

The current market already has seven approved products in the U.S. and a large number of research activities are currently undergoing in this segment generating interest of commercial as well as academic research institutions. In the current period of precision medicine and providing targeted treatment, identification of target patient has become very important as well as complicated. With the emergence of diagnostic test identifying predictive biomarkers, the selection and administration of targeted treatment has become comparativlely conveninent and efficient.

PD-1/PDL-1 inhibitors are majorly indicated for the treatment of advanced cases of different cancer indications. The PD-1/PDL-1 inibitor treatment has been found to be more effective in patients demonstrating certain level of predictive biomarkers such as PDL-1 expression. However, these tests are costly and treatment specific which poses a hinderance to smooth administration of these PD-1/PDL-1 inhibitors to larger set of patients.

Several players, such as MSD, Bristol Myers Squibb company (BMS), AstraZeneca Plc are among the leading companies actively pursuing research activities in maximizing the potential of PD-1/PDL-1 inhbitors. Companies in the Asia-Pacific region also have rich clinical pipeline and strategically pursuing research activities in this segment.

Breast Cancer Awareness Month | PD-1/PDL-1 inhibitor Competitive Landscape

There are seven product currently available in the market. The first entrant Keytruda drwas a significant share of the market followed by second entrant Opdivo. Imfinzi and Tecentriq also have their combined market share below 20%.

Disease Landscape

In terms of most promising indication for the application of PD-1/PDL-1 inhibitors, melanoma appears to be leading as highlighted by experts including data gathered from secondary research.

Segmentation:

Within the research report, the segmentation has made on the basis of:

• Identified cancer indicattions (Non-small cell lung cancer, melanoma, breast cancer, hepatocellular carcinoma, colorectal cancer, and urothelial carcinoma), and
• The seven major markets (the U.S., the U.K., Germany, France, Italy, Spain, and Japan).

This segmentation highlights value propositions and business models useful for industry leaders and stakeholders. The research also comprises country-level analysis, go-to-market strategies of leading players, and future opportunities, among others, to detail the scope and provide a 360-coverage of the domain.

Demand – Drivers and Challenges

Some of the potential drivers includes:

• Increased Use of PD-1/PDL-1 Inhibitors in Multiple Sub-set of Cancer Indications
• Increase in PD-1/PDL-1 Inhibitor Based Combination Regimens

The market is expected to face some limitations too due to the following challenges:

• Immune-related Adverse Events Associated With PD-1/PDL-1 Inhibitor Treatment are a Cause of Concern
• Treatment Specific Biomarkers Assays Pose Hinderance to Smooth Adoption of PD-1/PDL-1 Inhibitor Treatment

How can this report add value to an organization?

Product/Innovation Strategy: The report provides an exhaustive list of pipeline products which are currently in the development along with their developmental details in various indications. This can help organizations in understanding the research activities, which is the promising indication to pursue or which organization has the potential product to enter first into the market as well it can help the organization to assess where should they place themselves in order to get maximum benefit. This report which provides an insight into estimated patient population eligible to receive PD-1/PDL-1 under identified indications will help to evaluate the promising indications.

Growth/Marketing Strategy: In addition to pursuing research on exploring the benefits of PD-1/PDL-1 inhibitors in multiple cancer indications, companies are working to bring more safer and convenient PD-1/PDL-1 inhbitors while retaining or improved efficacy. The companies are exploring small molecules as well as alternative formulations for PD-1/PDL-1 inhibitors in an effort to make the administration relatively more convenient.

Competitive Strategy: Key players in the global PD-1/PDL-1 inhibitor market were analyzed and profiled in the study, who have commercially available PD-1/PDL-1 inhbitors as well as those who are developing and their products are in the clinical development. Moreover, a detailed competitive benchmarking of the players operating in the global PD-1/PDL-1 inhibitor market has been done to help the reader understand how players stand against each other, presenting a clear market landscape. Additionally, comprehensive competitive strategies such as partnerships, agreements, and collaborations will aid the reader in understanding the untapped revenue pockets in the market.

Key Companies Profiled

• GlaxoSmithKline plc
• Bristol-Myers Squibb Company
• Arcus Biosciences, Inc.
• Agenus Inc.
• F. Hoffmann-La Roche Ltd
• Astra Zeneca PLC
• Beigene Ltd.
• Shanghai Junshi Bioscience Co. Ltd.
• Shanghai Henlius Biotech, Inc.
• Jiangsu HengRui Medicine Co., Ltd.
• Lee’s Pharmaceutical Limited
• Incyte Corporation
• Biocad
• CStone Pharmaceuticals

Additional information

Publisher

Geography Covered

Date Published

Pages

Format

Currency

USD

Table of Contents

1 Market Definition 1.1 Inclusion and Exclusion Criteria 2 Research Scope 2.1 Target Audience 2.2 Key Questions Answered in the Report 3 Research Methodology 3.1 Global PD-1/PDL-1 Inhibitor Market: Research Methodology 3.2 Primary Data Sources 3.3 Secondary Data Sources 3.4 Target Patient Pool Estimation Model 3.5 Criteria for Company Profiling 4 Markets 4.1 Market Overview 4.2 PD-1/PDL-1 Inhibitors: Overview 4.2.1 PD-1/PDL-1 Inhibitors and their role in Cancer immunotherapy 4.2.2 Historic Development of PD-1/PDL-1 Inhibitors 4.2.3 Mechanism of Action of PD-1/PDL-1 Inhibitors 4.2.4 Market Landscape 4.2.4.1 Approved PD-1/PDL-1 Inhibitors 4.2.4.2 Competitive Landscape 4.2.4.2.1 Strategic Activities 4.2.4.2.2 Regional Distribution of Companies 4.2.5 Market Dynamics 4.2.5.1 Market Drivers 4.2.5.1.1 Increased Use of PD-1/PDL-1 Inhibitors in Multiple Sub-set of Cancer Indications 4.2.5.1.2 Increase in PD-1/PDL-1 Inhibitor Based Combination Regimens 4.2.5.2 Market Restraints 4.2.5.2.1 Immune-related Adverse Events Associated With PD-1/PDL-1 Inhibitor Treatment are a Cause of Concern 4.2.5.2.2 Treatment Specific Biomarkers Assays Pose Hinderance to Smooth Adoption of PD-1/PDL-1 Inhibitor Treatment 4.2.5.3 Opportunities 4.2.5.3.1 Promising Therapeutic Outcomes Generating Positive Market Sentiments 4.2.5.3.2 Demand for Safer and Convenient Formulation 5 Indications 5.1 Indications 5.1.1 Non-Small Cell Lung Cancer (NSCLC) 5.1.1.1 Non-Small Cell Lung Cancer (NSCLC): Disease Overview 5.1.1.2 Non-Small Cell Lung Cancer (NSCLC): Disease Pathophysiology 5.1.1.3 Non-Small Cell Lung Cancer (NSCLC): Treatment 5.1.2 Melanoma 5.1.2.1 Melanoma: Disease Overview 5.1.2.2 Melanoma: Disease Pathophysiology 5.1.2.3 Melanoma: Treatment 5.1.3 Hepatocellular Carcinoma (HCC) 5.1.3.1 Hepatocellular Carcinoma (HCC): Disease Overview 5.1.3.2 Hepatocellular Carcinoma (HCC): Disease Pathophysiology 5.1.3.3 Hepatocellular Carcinoma (HCC): Treatment 5.1.4 Colorectal Cancer (CRC) 5.1.4.1 Colorectal Cancer (CRC): Disease Overview 5.1.4.2 Colorectal Cancer (CRC): Disease Pathophysiology 5.1.4.3 Colorectal Cancer (CRC): Treatment 5.1.5 Breast Cancer 5.1.5.1 Breast Cancer: Disease Overview 5.1.5.2 Breast Cancer: Pathophysiology 5.1.5.3 Breast Cancer: Treatment 5.1.6 Urothelial Carcinoma 5.1.6.1 Urothelial Carcinoma: Disease Overview 5.1.6.2 Urothelial Carcinoma: Pathophysiology 5.1.6.3 Urothelial Carcinoma: Treatment 6 Products 6.1 Global PD-1/PDL-1 Inhibitor Pipeline Analysis (by Phase) 6.1.1 By Development Phase 6.1.2 By Drug Class 6.1.3 By Route of Administration (RoA) 6.1.4 By Monotherapy/Combination Therapy Type 6.1.5 By Target 7 Application 7.1 North America 7.1.1 Melanoma 7.1.1.1 Melanoma: Epidemiology 7.1.2 Breast Cancer 7.1.2.1 Breast Cancer: Epidemiology 7.1.3 Colorectal Cancer (CRC) 7.1.3.1 Colorectal Cancer (CRC): Epidemiology 7.1.4 Non-Small Cell Lung Cancer (NSCLC) 7.1.4.1 Non-Small Cell Lung Cancer (NSCLC): Epidemiology 7.1.5 Hepatocellular Carcinoma (HCC) 7.1.5.1 Hepatocellular Carcinoma (HCC): Epidemiology 7.1.6 Urothelial Carcinoma 7.1.6.1 Urothelial Carcinoma: Epidemiology 7.2 U.K. 7.2.1 Non-Small Cell Lung Cancer (NSCLC) 7.2.1.1 Non-Small Cell Lung Cancer (NSCLC): Epidemiology 7.2.2 Melanoma 7.2.2.1 Melanoma: Epidemiology 7.2.3 Hepatocellular Carcinoma (HCC) 7.2.3.1 Hepatocellular Carcinoma (HCC): Epidemiology 7.2.4 Colorectal Cancer (CRC) 7.2.4.1 Colorectal Cancer (CRC): Epidemiology 7.2.5 Breast Cancer 7.2.5.1 Breast Cancer: Epidemiology 7.2.6 Urothelial Carcinoma 7.2.6.1 Urothelial Carcinoma: Epidemiology 7.3 Germany 7.3.1 Non-Small Cell Lung Cancer (NSCLC) 7.3.1.1 Non-Small Cell Lung Cancer (NSCLC): Epidemiology 7.3.2 Melanoma 7.3.2.1 Melanoma: Epidemiology 7.3.3 Hepatocellular Carcinoma (HCC) 7.3.3.1 Hepatocellular Carcinoma (HCC): Epidemiology 7.3.4 Colorectal Cancer (CRC) 7.3.4.1 Colorectal Cancer (CRC): Epidemiology 7.3.5 Breast Cancer 7.3.5.1 Breast Cancer: Epidemiology 7.3.6 Urothelial Carcinoma 7.3.6.1 Urothelial Carcinoma: Epidemiology 7.4 France 7.4.1 Non-Small Cell Lung Cancer (NSCLC) 7.4.1.1 Non-Small Cell Lung Cancer (NSCLC): Epidemiology 7.4.2 Melanoma 7.4.2.1 Melanoma: Epidemiology 7.4.3 Hepatocellular Carcinoma (HCC) 7.4.3.1 Hepatocellular Carcinoma (HCC): Epidemiology 7.4.4 Colorectal Cancer (CRC) 7.4.4.1 Colorectal Cancer (CRC): Epidemiology 7.4.5 Breast Cancer 7.4.5.1 Breast Cancer: Epidemiology 7.4.6 Urothelial Carcinoma 7.4.6.1 Urothelial Carcinoma: Epidemiology 7.5 Italy 7.5.1 Non-Small Cell Lung Cancer (NSCLC) 7.5.1.1 Non-Small Cell Lung Cancer (NSCLC): Epidemiology 7.5.2 Melanoma 7.5.2.1 Melanoma: Epidemiology 7.5.3 Hepatocellular Carcinoma (HCC) 7.5.3.1 Hepatocellular Carcinoma (HCC): Epidemiology 7.5.4 Colorectal Cancer (CRC) 7.5.4.1 Colorectal Cancer (CRC): Epidemiology 7.5.5 Breast Cancer 7.5.5.1 Breast Cancer: Epidemiology 7.5.6 Urothelial Carcinoma 7.5.6.1 Urothelial Carcinoma: Epidemiology 7.6 Spain 7.6.1 Non-Small Cell Lung Cancer (NSCLC) 7.6.1.1 Non-Small Cell Lung Cancer (NSCLC): Epidemiology 7.6.2 Melanoma 7.6.2.1 Melanoma: Epidemiology 7.6.3 Hepatocellular Carcinoma (HCC) 7.6.3.1 Hepatocellular Carcinoma (HCC): Epidemiology 7.6.4 Colorectal Cancer (CRC) 7.6.4.1 Colorectal Cancer (CRC): Epidemiology 7.6.5 Breast Cancer 7.6.5.1 Breast Cancer: Epidemiology 7.6.6 Urothelial Carcinoma 7.6.6.1 Urothelial Carcinoma: Epidemiology 7.7 Japan 7.7.1 Non-Small Cell Lung Cancer (NSCLC) 7.7.1.1 Non-Small Cell Lung Cancer (NSCLC): Epidemiology 7.7.2 Melanoma 7.7.2.1 Melanoma: Epidemiology 7.7.3 Hepatocellular Carcinoma (HCC) 7.7.3.1 Hepatocellular Carcinoma (HCC): Epidemiology 7.7.4 Colorectal Cancer (CRC) 7.7.4.1 Colorectal Cancer (CRC): Epidemiology 7.7.5 Breast Cancer 7.7.5.1 Breast Cancer: Epidemiology 7.7.6 Urothelial Carcinoma 7.7.6.1 Urothelial Carcinoma: Epidemiology 8 Markets - Competitive Benchmarking & Company Profiles 8.1 GlaxoSmithKline plc 8.1.1 Company Overview 8.1.2 Role of GlaxoSmithKline plc in Global PD-1/PDL-1 Inhibitor Market 8.1.3 Product Portfolio 8.1.4 Key Competitors of the Company 8.1.5 Financials 8.1.6 Key Insights About Financial Health of the Company 8.1.7 Business Strategies 8.1.7.1 Product Developments 8.1.8 Corporate Strategies 8.1.8.1 Partnership and Collaboration 8.1.9 Analyst’s Perspective 8.2 Bristol-Myers Squibb Company 8.2.1 Company Overview 8.2.2 Role of Bristol-Myers Squibb Company in Global PD-1/PDL-1 Inhibitor Market 8.2.3 Product Portfolio 8.2.4 Key Competitors of the Company 8.2.5 Financials 8.2.6 Key Insights About Financial Health of the Company 8.2.7 Business Strategies 8.2.7.1 Product Developments 8.2.8 Corporate Strategies 8.2.8.1 Merger and Acquisitions 8.2.9 Analyst’s Perspective 8.3 Arcus Biosciences, Inc. 8.3.1 Company Overview 8.3.2 Role of Arcus Biosciences, Inc. in Global PD 1/PDL-1 inhibitor Market 8.3.3 Product Portfolio 8.3.4 Key Competitors of the Company 8.3.5 Financials 8.3.6 Key Insights About Financial Health of the Company 8.3.7 Business Strategies 8.3.7.1 Product Developments 8.3.8 Corporate Strategies 8.3.8.1 Partnerships and Collaboration 8.3.9 Analyst’s Perspective 8.4 Agenus Inc. 8.4.1 Company Overview 8.4.2 Role of Agenus Inc. in Global PD 1/PDL-1 Inhibitor Market 8.4.3 Product Portfolio 8.4.4 Financials 8.4.5 Key Insights About Financial Health of the Company 8.4.6 Business Strategies 8.4.6.1 Product Developments 8.4.7 Corporate Strategies 8.4.7.1 Partnerships and Collaboration 8.4.8 Analyst’s Perspective 8.5 F. Hoffmann-La Roche Ltd 8.5.1 Company Overview 8.5.2 Role of F. Hoffmann-La Roche Ltd in Global PD 1/PDL-1 inhibitor Market 8.5.3 Product Portfolio 8.5.4 Key Competitors of the Company 8.5.5 Financials 8.5.6 Key Insights About Financial Health of the Company 8.5.7 Business Strategies 8.5.7.1 Product Developments 8.5.8 Corporate Strategies 8.5.8.1 Partnership and Collaboration 8.5.9 Analyst’s Perspective 8.6 Astra Zeneca PLC 8.6.1 Company Overview 8.6.2 Role of Astra Zeneca PLC in Global PD 1/PDL-1 inhibitor Market 8.6.3 Product Portfolio 8.6.4 Key Competitors of the Company 8.6.5 Financials 8.6.6 Key Insights About Financial Health of the Company 8.6.7 Business Strategies 8.6.7.1 Product Developments 8.6.8 Corporate Strategies 8.6.8.1 Partnership and Collaboration 8.6.9 Analyst’s Insight 8.7 Beigene Ltd. 8.7.1 Company Overview 8.7.2 Role of Beigene Ltd. in Global PD 1/PDL-1 inhibitor Market 8.7.3 Product Portfolio 8.7.4 Key Competitors of the Company 8.7.5 Financials 8.7.6 Key Insights About Financial Health of the Company 8.7.7 Business Strategies 8.7.7.1 Product Developments 8.7.8 Corporate Strategies 8.7.8.1 Partnership and Collaboration 8.7.9 Analyst’s Perspective 8.8 Shanghai Junshi Bioscience Co. Ltd. 8.8.1 Company Overview 8.8.2 Role of Shanghai Junshi Bioscience Co., Ltd. in Global PD 1/PDL-1 inhibitor Market 8.8.3 Product Portfolio 8.8.4 Key Competitors of the Company 8.8.5 Financials 8.8.6 Key Insights About Financial Health of the Company 8.8.7 Business Strategies 8.8.7.1 Product Developments 8.8.8 Corporate Strategies 8.8.8.1 Partnership and Collaboration 8.8.9 Analyst’s Perspective 8.9 Shanghai Henlius Biotech, Inc. 8.9.1 Company Overview 8.9.2 Role of Shanghai Henlius Biotech, Inc. in Global PD 1/PDL-1 inhibitor Market 8.9.3 Product Portfolio 8.9.4 Key Competitors of the Company 8.9.5 Financials 8.9.6 Key Insights About Financial Health of the Company 8.9.7 Business Strategies 8.9.7.1 Product Developments 8.9.8 Corporate Strategies 8.9.8.1 Partnership and Collaboration 8.9.9 Analyst’s Perspective 8.1 Jiangsu HengRui Medicine Co., Ltd. 8.10.1 Company Overview 8.10.2 Role of Jiangsu HengRui Medicine Co., Ltd. in Global PD 1/PDL-1 Inhibitor Market 8.10.3 Product Portfolio 8.10.4 Key Competitors of the Company 8.10.5 Financials 8.10.6 Key Insights About Financial Health of the Company 8.10.7 Business Strategies 8.10.7.1 Product Developments 8.10.8 Corporate Strategies 8.10.8.1 Partnership and Collaboration 8.10.9 Analyst’s Perspective 8.11 Lee's Pharmaceutical Limited 8.11.1 Company Overview 8.11.2 Role of Lee's Pharmaceutical Limited in Global PD 1/PDL-1 inhibitor Market 8.11.3 Product Portfolio 8.11.4 Key Competitors of the Company 8.11.5 Financials 8.11.6 Key Insights About Financial Health of the Company 8.11.7 Business Strategies 8.11.7.1 Product Developments 8.11.8 Analyst’s Perspective 8.12 Incyte Corporation 8.12.1 Company Overview 8.12.2 Role of Incyte Corporation in Global PD-1/PDL-1 inhibitors Market 8.12.3 Product Portfolio 8.12.4 Key Competitors of the Company 8.12.5 Financials 8.12.6 Key Insights About Financial Health of the Company 8.12.7 Business Strategies 8.12.7.1 Product Developments 8.12.8 Corporate Strategies 8.12.8.1 Collaboration and Agreement 8.12.9 Analyst’s Perspective 8.13 Biocad 8.13.1 Company Overview 8.13.2 Role of Biocad in Global PD-1/PDL-1 Inhibitors Market 8.13.3 Product Portfolio 8.13.4 Key Competitors of the Company 8.13.5 Business Strategies 8.13.5.1 Product Developments 8.13.6 Corporate Strategies 8.13.6.1 Partnership and Collaboration 8.13.7 Analyst’s Perspective 8.14 CStone Pharmaceuticals 8.14.1 Company Overview 8.14.2 Role of CStone Pharmaceuticals in Global PD-1/PDL-1 Inhibitors Market 8.14.3 Product Portfolio 8.14.4 Key Competitors of the Company 8.14.5 Financials 8.14.6 Key Insights About Financial Health of the Company 8.14.7 Business Strategies 8.14.7.1 Product Developments 8.14.8 Corporate Strategies 8.14.8.1 Partnership and Collaboration 8.14.9 Analyst’s Perspective 9 BIS Research Recommendations 9.1 Current Market Scenario 9.2 Future Scenario 9.3 Key Success Factors and Challenges 9.3.1 Success Factors 9.3.2 Key Challenges List of Figures Figure 1: PD-1/PDL-1 Inhibitor Market Share (by Sales), $Million, 2021 Figure 2: Number of Eligible Patients Specific to Indication for 2022 Figure 3: Global PD-1/PDL-1 Inhibitor Market Segmentation Figure 4: Global PD-1/PDL-1 Inhibitor Market Methodology Figure 5: Primary Research Methodology Figure 6: Historic Development of PD-1/PDL-1 Inhibitors Figure 7: Role of PD-1/PDL-1 in Tumor Protection Figure 8: Key Market Players (by Sales), $Million, 2021 Figure 9: Number of Strategic Activities Figure 10: Regional Distribution of Companies Figure 11: Non-Small Cell Lung Cancer (NSCLC) Disease Pathophysiology Figure 12: Melanoma Disease Pathophysiology Figure 13: Melanoma: Treatment Options Figure 14: Hepatocellular Carcinoma (HCC): Disease Pathophysiology Figure 15: Hepatocellular Carcinoma (HCC) Treatment Figure 16: Hepatocellular Carcinoma (HCC) Treatment Algorithm Figure 17: Chromosomal Instability (CIN) Pathway and Microsatellite Instability (MSI) Pathway Figure 18: Serrated Pathway Figure 19: Colorectal Cancer (CRC): Treatment Algorithm Figure 20: Breast Cancer: Disease Pathophysiology Figure 21: Breast Cancer: Treatment Figure 22: Urothelial Carcinoma: Disease Pathophysiology Figure 23: Urothelial Carcinoma Treatment Types Figure 24: Urothelial Carcinoma Treatment Algorithm Figure 25: Number of PD-1/PDL-1 Inhibitor Clinical Trials Figure 26: Number of Clinical Trials by Drug Class Figure 27: PD-1/PDL-1 Inhibitor by Therapy (Monotherapy/Combination) Type Figure 28: PD-1/PDL-1 Inhibitors with Added Entity Figure 29: U.S. Eligible Population for PD-1/PDL-1 Inhibitor Treatment Figure 30: U.S. Eligible Patient Population for Melanoma, 2022-2032 Figure 31: U.S. Eligible Patient Population for Breast Cancer, 2022-2032 Figure 32: U.S. Eligible Patient Population for Colorectal Cancer, 2022-2032 Figure 33: U.S. Eligible Patient Population for NSCLC, 2022-2032 Figure 34: U.S. Eligible Patient Population for Hepatocellular Carcinoma, 2022-2032 Figure 35: U.S. Eligible Patient Population for Urothelial Carcinoma, 2022-2032 Figure 36: U.K. Eligible Population for PD-1/PDL-1 Inhibitor Treatment Figure 37: U.K. Eligible Patient Population for NSCLC, 2022-2032 Figure 38: U.K. Eligible Patient Population for Melanoma, 2022-2032 Figure 39: U.K. Eligible Patient Population for Hepatocellular Carcinoma, 2022-2032 Figure 40: U.K. Eligible Patient Population for Colorectal Cancer, 2022-2032 Figure 41: U.K. Eligible Patient Population for Breast Cancer, 2022-2032 Figure 42: U.K. Eligible Patient Population for Urothelial Carcinoma, 2022-2032 Figure 43: Germany Eligible Population for PD-1/PDL-1 Inhibitor Treatment Figure 44: Germany: Eligible Patient Population for NSCLC, 2022-2032 Figure 45: Germany: Eligible Patient Population for Melanoma, 2022-2032 Figure 46: Germany: Eligible Patient Population for Hepatocellular Carcinoma, 2022-2032 Figure 47: Germany: Eligible Patient Population for Colorectal Cancer, 2022-2032 Figure 48: Germany: Eligible Patient Population for Breast Cancer, 2022-2032 Figure 49: Germany: Eligible Patient Population for Urothelial Carcinoma, 2022-2032 Figure 50: France Eligible Population for PD-1/PDL-1 Inhibitor Treatment Figure 51: France: Eligible Patient Population for NSCLC, 2022-2032 Figure 52: France: Eligible Patient Population for Melanoma, 2022-2032 Figure 53: France: Eligible Patient Population for Hepatocellular Carcinoma, 2022-2032 Figure 54: France: Eligible Patient Population for Colorectal Cancer, 2022-2032 Figure 55: France: Eligible Patient Population for Breast Cancer, 2022-2032 Figure 56: France: Eligible Patient Population for Urothelial Carcinoma, 2022-2032 Figure 57: Italy Eligible Population for PD-1/PDL-1 Inhibitor Treatment Figure 58: Italy: Eligible Patient Population for NSCLC, 2022-2032 Figure 59: Italy: Eligible Patient Population for Melanoma, 2022-2032 Figure 60: Italy: Eligible Patient Population for Hepatocellular Carcinoma, 2022-2032 Figure 61: Italy: Eligible Patient Population for Colorectal Cancer, 2022-2032 Figure 62: Italy: Eligible Patient Population for Breast Cancer, 2022-2032 Figure 63: Italy: Eligible Patient Population for Urothelial Carcinoma, 2022-2032 Figure 64: Spain Eligible Population for PD-1/PDL-1 Inhibitor Treatment Figure 65: Spain: Eligible Patient Population for NSCLC, 2022-2032 Figure 66: Spain: Eligible Patient Population for Melanoma, 2022-2032 Figure 67: Spain: Eligible Patient Population for Hepatocellular Carcinoma, 2022-2032 Figure 68: Spain: Eligible Patient Population for Colorectal Cancer, 2022-2032 Figure 69: Spain: Eligible Patient Population for Breast Cancer, 2022-2032 Figure 70: Spain: Eligible Patient Population for Urothelial Carcinoma, 2022-2032 Figure 71: Japan Eligible Population for PD-1/PDL-1 Inhibitor Treatment Figure 72: Japan: Eligible Patient Population for NSCLC, 2022-2032 Figure 73: Japan: Eligible Patient Population for Melanoma, 2022-2032 Figure 74: Japan: Eligible Patient Population for Hepatocellular Carcinoma, 2022-2032 Figure 75: Japan: Eligible Patient Population for Colorectal Cancer, 2022-2032 Figure 76: Japan: Eligible Patient Population for Breast Cancer, 2022-2032 Figure 77: Japan: Eligible Patient Population for Urothelial Carcinoma, 2022-2032 Figure 78: GlaxoSmithKline plc: Product Portfolio Figure 79: GlaxoSmithKline plc: Overall Financials, $Million, 2019-2021 Figure 80: GlaxoSmithKline plc: Net Revenue (by Segment), $Million, 2019-2021 Figure 81: GlaxoSmithKline plc: Net Revenue (by Region), $Million, 2019-2021 Figure 82: GlaxoSmithKline plc: R&D Expenditure, $Million, 2019-2021 Figure 83: Bristol-Myers Squibb Company: Product Portfolio Figure 84: Bristol-Myers Squibb Company: Overall Financials, $Million, 2019-2021 Figure 85: Bristol-Myers Squibb Company: Net Revenue (by Region), $Million, 2019-2021 Figure 86: Bristol-Myers Squibb Company: R&D Expenditure, $Million, 2019-2021 Figure 87: Arcus Biosciences, Inc.: Product Portfolio Figure 88: Arcus Biosciences, Inc.: Overall Financials, $Million, 2019-2021 Figure 89: Arcus Biosciences, Inc.: R&D Expenditure, $Million, 2019-2021 Figure 90: Agenus Inc.: Product Portfolio Figure 91: Agenus Inc.: Overall Financials, $Million, 2019-2021 Figure 92: Agenus Inc.: Net Revenue (by Region), $Million, 2019-2021 Figure 93: Agenus Inc.: R&D Expenditure, $Million, 2019-2021 Figure 94: F. Hoffmann-La Roche Ltd: Product Portfolio Figure 95: F. Hoffmann-La Roche Ltd: Overall Financials, $Million, 2019-2021 Figure 96: F. Hoffmann-La Roche Ltd: Net Revenue (by Segment), $Million, 2019-2021 Figure 97: F. Hoffmann-La Roche Ltd: R&D Expenditure, $Million, 2019-2021 Figure 98: Astra Zeneca PLC: Product Portfolio Figure 99: Astra Zeneca PLC: Overall Financials, $Million, 2019-2021 Figure 100: Astra Zeneca PLC: Net Revenue (by Region), $Million, 2019-2021 Figure 101: Astra Zeneca PLC: R&D Expenditure, $Million, 2019-2021 Figure 102: Beigene Ltd.: Product Portfolio Figure 103: Beigene Ltd.: Overall Financials, $Million, 2019-2021 Figure 104: Beigene Ltd.: R&D Expenditure, $Million, 2019-2021 Figure 105: Shanghai Junshi Bioscience Co., Ltd.: Product Portfolio Figure 106: Shanghai Junshi Bioscience Co., Ltd.: Overall Financials, $Million, 2019-2021 Figure 107: Shanghai Junshi Bioscience Co., Ltd.: R&D Expenditure, $Million, 2019-2021 Figure 108: Shanghai Henlius Biotech, Inc.: Product Portfolio Figure 109: Shanghai Henlius Biotech, Inc.: Overall Financials, $Million, 2019-2021 Figure 110: Shanghai Henlius Biotech, Inc.: R&D Expenditure, $Million, 2019-2021 Figure 111: Jiangsu HengRui Medicine Co., Ltd.: Product Portfolio Figure 112: Jiangsu HengRui Medicine Co., Ltd.: Overall Financials, $Million, 2019-2021 Figure 113: Jiangsu HengRui Medicine Co., Ltd.: R&D Expenditure, $Million, 2019-2021 Figure 114: Lee's Pharmaceutical Limited: Product Portfolio Figure 115: Lee's Pharmaceutical Limited: Overall Financials, $Million, 2019-2021 Figure 116: Lee's Pharmaceutical Limited: R&D Expenditure, $Million, 2019-2021 Figure 117: Incyte Corporation: Product Portfolio Figure 118: Incyte Corporation: Overall Financials, $Million, 2019-2021 Figure 119: Incyte Corporation R&D Expenditure, $Million, 2019-2021 Figure 120: Biocad: Product Portfolio Figure 121: CStone Pharmaceuticals: Product Portfolio Figure 122: CStone Pharmaceuticals: Overall Financials, $Million, 2019-2021 Figure 123: CStone Pharmaceuticals: Revenue (by Region), $Million, 2019-2021 Figure 124: CStone Pharmaceuticals: R&D Expenditure, $Million, 2019-2021 List of Tables Table 1: Approved PD-1/PDL-1 Inhibitors Table 2: Snapshot: Approved PD-1/PDL-1 Inhibitors Table 3: Companies by Region Table 4: Number of Indication Added Since Launch Table 5: Combination Regimen with PD-1/PDL-1 Inhibitors Table 6: Non-Small Cell Lung Cancer (NSCLC): Stage Specific Treatment Options Table 7: Stage-Wise Colorectal Cancer (CRC) Treatment Table 8: Systemic Therapy for Distant Recurrence Cases of Colorectal Cancer (CRC) Table 9: PD-1/PDL-1 Inhibitor by Route of Administration (RoA) Table 10: Combination Regimes by Development Stage Table 11: Leading PD-1/PDL-1 Inhibitors and Indications in Combination Therapy Table 12: Leading PD-1/PDL-1 Inhibitors as Monotherapy and Target Indication Table 13: U.S. Incidence for Cancer Indications, 2022-2032 Table 14: U.S. Prevalence for Cancer Indications, 2022-2032 Table 15: U.K. Incidence for Cancer Indications, 2022-2032 Table 16: U.K. Prevalence for Cancer Indications, 2022-2032 Table 17: Germany Incidence for Cancer Indications, 2022-2032 Table 18: Germany Prevalence for Cancer Indications, 2022-2032 Table 19: France Incidence for Cancer Indications, 2022-2032 Table 20: France Prevalence for Cancer Indications, 2022-2032 Table 21: Italy Incidence for Cancer Indications, 2022-2032 Table 22: Italy Prevalence for Cancer Indications, 2022-2032 Table 23: Spain Incidence for Cancer Indications, 2022-2032 Table 24: Spain Prevalence for Cancer Indications, 2022-2032 Table 25: Japan Incidence for Cancer Indications, 2022-2032 Table 26: Japan Prevalence for Cancer Indications, 2022-2032 Table 27: GlaxoSmithKline plc: Key Competitors Table 28: Product Development Table 29: Partnership and Collaboration Table 30: Potential Registrational Study Readouts Anticipated Through 2023/2024 Table 31: Bristol-Myers Squibb Company: Key Competitors Table 32: Product Developments Table 33: Merger and Acquisitions Table 34: Arcus Biosciences, Inc.: Key Competitors Table 35: Product Developments Table 36: Partnerships and Collaboration Table 37: Product Developments Table 38: Partnerships and Collaboration Table 39: F. Hoffmann-La Roche Ltd: Key Competitors Table 40: Product Developments Table 41: Partnership and Collaboration Table 42: Astra Zeneca PLC: Key Competitors Table 43: Product Developments Table 44: Partnership and Collaboration Table 45: Beigene Ltd.: Key Competitors Table 46: Product Developments Table 47: Partnership and Collaboration Table 48: Shanghai Junshi Bioscience Co., Ltd.: Key Competitors Table 49: Product Developments Table 50: Partnership and Collaboration Table 51: Shanghai Henlius Biotech, Inc.: Key Competitors Table 52: Product Developments Table 53: Partnership and Collaboration Table 54: Jiangsu HengRui Medicine Co., Ltd.: Key Competitors Table 55: Product Developments Table 56: Partnership and Collaboration Table 57: Lee's Pharmaceutical Limited: Key Competitors Table 58: Product Developments Table 59: Product Developments Table 60: Collaboration and Agreement Table 61: Product Developments Table 62: Partnership and Collaboration Table 63: Product Developments Table 64: Partnership and Collaboration

Companies Mentioned

GlaxoSmithKline plc Bristol-Myers Squibb Company Arcus Biosciences, Inc. Agenus Inc. F. Hoffmann-La Roche Ltd Astra Zeneca PLC Beigene Ltd. Shanghai Junshi Bioscience Co. Ltd. Shanghai Henlius Biotech, Inc. Jiangsu HengRui Medicine Co., Ltd. Lee's Pharmaceutical Limited Incyte Corporation Biocad CStone Pharmaceuticals

Reviews

There are no reviews yet.

Be the first to review “PD-1/PDL-1 Inhibitor Market – A Global and Regional Analysis: Focus on Epidemiology, Product, and Region – Analysis and Forecast, 2022-2032”

Related products